Overview

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Status:
Active, not recruiting
Trial end date:
2022-11-29
Target enrollment:
Participant gender:
Summary
International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Allopurinol
Verinurad